CWNM News Out! Pharmaceutical Company Achieves Positive In-Vitro Testing Results Diabetes Drug

CORAL SPRINGS, Florida, January 31, 2013 /PRNewswire via COMTEX/ -- Crown Marketing Pharmaceuticals (OTC: CWNM) announced today that it has achieved positive in-vitro testing results of the most widely prescribed Diabetes drug commonly known as Metformin. Crown's Controlled Drug Delivery Device (CDDT) is less than half the size of the 500mg dosage tablet, and may reduce and ameliorate many of the gastrointestinal side effects of Metformin. The most common adverse effects of Metformin are gastrointestinal upset including diarrhea, cramps, nausea and vomiting. Crown Marketing Pharmaceuticals (OTC: CWNM) believes it can significantly reduce or eliminate these effects with its patented technology.